Long-term exercise training decreases interleukin-6 (IL-6) serum levels in subjects with impaired glucose tolerance: effect of the -174G/C variant in IL-6 gene

Eur J Endocrinol. 2008 Aug;159(2):129-36. doi: 10.1530/EJE-08-0220. Epub 2008 May 9.

Abstract

Objective: Exercise training has been shown to have anti-inflammatory effects in patients with type 2 diabetes. Changes in interleukin-6 (IL-6) serum concentrations in response to training could contribute to these beneficial effects. However, there are heterogeneous data on whether circulating IL-6 is altered by exercise training. We therefore hypothesize that genetic factors modify the individual changes in IL-6 levels after long-term training.

Research design and methods: The -174G/C variant in the IL-6 gene was genotyped in 60 subjects with impaired glucose tolerance. For a 12-month interventional study, patients were randomized into three groups: a control group (n=16) was compared with one group, which underwent a standardized training program (n=24) and another group, which was treated with 4 mg rosiglitazone once daily (n=20). At baseline, after 1, 6, and 12 months, we measured anthropometric parameters and serum concentration of IL-6 and, at baseline and after 12 months, we determined glucose tolerance and fitness level.

Results: Only in subjects carrying the SNP -174C allele did long-term exercise training result in significantly reduced IL-6 serum concentrations. Multivariate linear regression analysis identified the IL-6 genotype as a significant predictor of changes in IL-6 serum concentrations independent of age, gender and improvement in body mass index, hemoglobin (Hb)A(1c), and fitness level in response to training.

Conclusions: Genetic variants in the IL-6 gene significantly modify changes in IL-6 serum concentrations in response to long-term exercise training programs. Our data suggest that genetic factors are important determinants for the individual response to anti-inflammatory effects of exercise training.

Publication types

  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Diabetes Mellitus, Type 2 / blood
  • Diabetes Mellitus, Type 2 / drug therapy
  • Diabetes Mellitus, Type 2 / genetics
  • Down-Regulation / genetics
  • Exercise / physiology*
  • Female
  • Genotype
  • Glucose Intolerance / blood*
  • Glucose Intolerance / genetics
  • Humans
  • Hypoglycemic Agents / therapeutic use
  • Interleukin-6 / blood*
  • Interleukin-6 / genetics*
  • Male
  • Middle Aged
  • Physical Endurance / physiology
  • Polymorphism, Single Nucleotide* / physiology
  • Rosiglitazone
  • Thiazolidinediones / therapeutic use
  • Time Factors

Substances

  • Hypoglycemic Agents
  • Interleukin-6
  • Thiazolidinediones
  • Rosiglitazone